Compare TAOP & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | NCEL |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | China | Switzerland |
| Employees | N/A | 11 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 13.2M |
| IPO Year | 2012 | N/A |
| Metric | TAOP | NCEL |
|---|---|---|
| Price | $1.30 | $2.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 15.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.89 |
| 52 Week High | $8.78 | $4.70 |
| Indicator | TAOP | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 48.64 |
| Support Level | $1.21 | $2.63 |
| Resistance Level | $1.59 | $3.19 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.44 | 24.44 |
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.